Search results

706 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Clinical guidelines Remove Clinical guidelines filter
Medical technologies guidance Remove Medical technologies guidance filter
Safe staffing guidelines Remove Safe staffing guidelines filter
Social care guidelines Remove Social care guidelines filter

Sleepio for adults with difficulty sleeping (MT443)

In development [GID-MT552] Expected publication date: 03 August 2021

Type

Medical technologies guidance

Status

In development
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education

In development [GID-NG10113] Expected publication date: 19 January 2022

Type

NICE guideline

Status

In development
Adults with complex needs: social work interventions including assessment, care management and support

In development [GID-NG10145] Expected publication date: 27 April 2022

Type

NICE guideline

Status

In development
Advocacy services for adults with health and social care needs

In development [GID-NG10156] Expected publication date: TBC

Type

NICE guideline

Status

In development
Safeguarding adults in care homes

In development [GID-NG10107] Expected publication date: 26 February 2021

Type

NICE guideline

Status

In development
Multiple myeloma - lenalidomide (maintenance, post autologous stem cell transplantation) [ID475]

In development [GID-TAG430] Expected publication date: 03 March 2021

Type

Technology appraisal guidance

Status

In development
Baricitinib for treating moderate to severe atopic dermatitis [ID1622]

In development [GID-TA10562] Expected publication date: 03 March 2021

Type

Technology appraisal guidance

Status

In development
GID-MT550 DyeVert for reducing contrast media in coronary and peripheral angiography (MT488)

In development [GID-MT550] Expected publication date: 04 October 2021

Type

Medical technologies guidance

Status

In development
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)

In development [GID-MT526] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
GID-MT554 KardiaMobile for the ambulatory detection of atrial fibrillation

In development [GID-MT554] Expected publication date: 06 January 2022

Type

Medical technologies guidance

Status

In development
GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)

In development [GID-MT557] Expected publication date: 22 March 2022

Type

Medical technologies guidance

Status

In development
MT507 Plus Sutures for preventing surgical site infection

In development [GID-MT558] Expected publication date: 09 November 2021

Type

Medical technologies guidance

Status

In development
GID-MT561 ClearGuard HD Antimicrobial Barrier Cap for preventing haemodialysis catheter-related bloodstream infections

In development [GID-MT561] Expected publication date: 02 February 2022

Type

Medical technologies guidance

Status

In development
Synergo for non-muscle-invasive bladder cancer

In development [GID-MT553] Expected publication date: 30 November 2021

Type

Medical technologies guidance

Status

In development
Alpha Stim AID (MT477)

In development [GID-MT542] Expected publication date: 08 March 2021

Type

Medical technologies guidance

Status

In development
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MT241)

In development [GID-MT548] Expected publication date: 04 May 2021

Type

Medical technologies guidance

Status

In development
Endo-SPONGE for treating low rectal anastomotic leakage (MT461)

In development [GID-MT539] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Peezy Midstream for urine collection (MT446)

In development [GID-MT538] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
The MAGEC system for spinal lengthening in children with scoliosis

In development [GID-MT544] Expected publication date: 15 September 2020

Type

Medical technologies guidance

Status

In development
Prontosan for acute and chronic wounds

In development [GID-MT551] Expected publication date: 05 October 2021

Type

Medical technologies guidance

Status

In development
DHT pilot: myCOPD for self-management of chronic obstructive pulmonary disease (COPD)

In development [GID-MT531] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
3C Patch System for treating diabetic foot ulcers (MT539)

In development [GID-MT559] Expected publication date: 19 January 2022

Type

Medical technologies guidance

Status

In development
MT476 UroShield for preventing catheter-associated urinary tract infections

In development [GID-MT560] Expected publication date: 15 March 2022

Type

Medical technologies guidance

Status

In development
MT582 AnaConDa-S for sedation with volatile anaesthetics in intensive care

In development [GID-MT556] Expected publication date: 23 February 2022

Type

Medical technologies guidance

Status

In development
Danis Stent for acute oesophageal variceal bleeds (MT450)

In development [GID-MT537] Expected publication date: 08 April 2021

Type

Medical technologies guidance

Status

In development
Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer [ID1678]

In development [GID-TA10587] Expected publication date: 02 June 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]

In development [GID-TA10472] Expected publication date: 02 June 2021

Type

Technology appraisal guidance

Status

In development
Empagliflozin for treating chronic heart failure with reduced ejection fraction [ID3826]

Proposed [GID-TA10719] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]

Proposed [GID-TA10733] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587

Proposed [GID-TA10519] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF Review of TA492) ID3777

Proposed [GID-TA10810] Expected publication date: 22 October 2021

Type

Technology appraisal guidance

Status

Proposed
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

Proposed [GID-TA10453] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Dulaglutide for treating type 2 diabetes [ID1451]

Proposed [GID-TA10439] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Gosuranemab for treating progressive supranuclear palsy [ID1607]

Proposed [GID-TA10553] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)

Proposed [GID-TA10306] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]

Proposed [GID-TA10802] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

Proposed [GID-TA10803] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after trastuzumab or a taxane [ID3909]

Proposed [GID-TA10804] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]

Proposed [GID-TA10788] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Timrepigene emparvovec for treating choroideremia [ID3916]

Proposed [GID-TA10787] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab for adjuvant treatment of resected stage 2 melanoma with high risk of recurrence [ID3908 ]

Proposed [GID-TA10786] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Polatuzumab vedotin with R-CHP for untreated diffuse large B-cell lymphoma [ID3901 ]

Proposed [GID-TA10785] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907 ]

Proposed [GID-TA10784] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pegunigalsidase alfa for treating Fabry disease [ID3904]

Proposed [GID-TA10790] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Leriglitazone for treating X-linked andrenoleukodystrophy [ID 3903]

Proposed [GID-TA10789] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Durvalumab with chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]

Proposed [GID-TA10783] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ]

Proposed [GID-TA10791] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]

Proposed [GID-TA10795] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900]

Proposed [GID-TA10792] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tezepelumab for maintenance treatment of uncontrolled severe asthma in people aged 12 and over [ID3910]

Proposed [GID-TA10796] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed